BeOne Medicines (ONC) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed BeOne Medicines (ONC) over the past year, gaining 27.0% versus a gain of 6.6%. Over five years, TAK leads with a +30.3% price change compared with +1.6% for ONC. Takeda Pharmaceutical is the larger company by market cap ($58.41 billion vs $38.92 billion), about 1.5 times the size.
On valuation, BeOne Medicines trades at a lower forward P/E (33.4x vs 34.5x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1093.79%, while BeOne Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | TAK |
|---|---|---|
| Share price | $342.07 | $18.29 |
| Market cap | $38.92B | $58.41B |
| 1-day change | -6.03% | -0.46% |
| YTD return | +19.82% | +17.83% |
| 1-year return | +6.56% | +27.04% |
| 5-year return | +1.56% | +30.28% |
| P/E ratio (TTM) | 61.19 | — |
| Forward P/E | 33.37 | 34.50 |
| EPS (TTM) | $5.59 | $-0.34 |
| Dividend yield | 0.00% | 1093.79% |
| Annual dividend | $0.00 | $200.00 |
| Revenue (latest FY) | $5.34B | — |
| Revenue growth (YoY) | +40.23% | — |
| Net income (latest FY) | $286.93M | — |
| Gross margin | 87.49% | — |
| Operating margin | 8.37% | — |
| Net margin | 5.37% | — |
| 52-week high | $385.22 | $19.10 |
| 52-week low | $253.95 | $12.99 |
| Distance from 52-week high | -11.20% | -4.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +27.23% | +20.10% |
| Average volume | 388.88K | 3.02M |
| Shares outstanding | 104.92M | 3.19B |
| Employees | 12,000 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed ONC by 20.5 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1093.79% vs 0.00%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
ONC vs TAK FAQ
Which is bigger, BeOne Medicines or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $58.41B compared with $38.92B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ONC or TAK?
TAK returned +27.04% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BeOne Medicines or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 1093.79%, while BeOne Medicines does not currently pay a regular dividend.
Are BeOne Medicines and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.